For millions of adults, the world does not go dark all at once; instead, it fades from the center outward. This is the hallmark of advanced dry age-related macular degeneration (AMD), specifically a condition known as geographic atrophy. When the macula—the part of the retina responsible for sharp, straight-ahead vision—deteriorates, simple acts like reading a prescription label, recognizing a grandchild’s face, or navigating a menu grow daily negotiations with a persistent central blind spot.
For decades, medical intervention for geographic atrophy focused almost exclusively on slowing the progression of the disease. While newer complement-inhibitor drugs can reduce the growth of lesions, they cannot restore the light-sensing cells already lost. Although, a new approach combining a subretinal implant and medical-grade smart glasses is attempting to bridge that gap, offering a way to restore vision using an implant and smart glasses to bypass damaged photoreceptors.
The system, known as PRIMA, does not aim to provide a total cure or a return to “perfect” sight. Instead, it functions as a partial repair of a broken sensory channel. By pairing a microscopic silicon array with digital image processing, researchers have demonstrated that patients can regain “form vision”—the ability to identify letters, numbers, and shapes—which had previously been considered irreversible.
In a key confirmatory study called PRIMAvera, 38 participants aged 60 and older were enrolled across 17 sites in five European countries. By the 12-month endpoint, investigators estimated that approximately 80% of the group achieved clinically meaningful improvement. Many participants regained the ability to read letters and words, with some reaching a visual acuity equivalent to 20/42 after one year of use and training.
The Engineering: How the ‘Vision Stack’ Works
The PRIMA system is less like a traditional piece of eyewear and more like a coordinated technology stack. The process begins with a pair of transparent glasses equipped with a camera. These glasses capture the visual scene and send the data to a pocket processor, which refines the image using digital enhancements like zoom and contrast. This processed image is then projected onto the eye using near-infrared light at 880 nm.
Under the retina, surgeons place a silicon array measuring just 2 mm by 2 mm and only 30 micrometers thick. This implant contains 378 photovoltaic pixels. When the near-infrared light hits these pixels, they convert the light into electrical pulses. These pulses stimulate the surviving retinal bipolar cells, which then send the signal through the optic nerve to the brain.
Crucially, because the glasses are transparent, users can merge this prosthetic central vision with their own preserved peripheral sight. In geographic atrophy, the edges of the visual field often remain intact; PRIMA simply fills in the missing center.
From Laboratory Flashes to Functional Reading
Earlier generations of retinal prostheses, such as the Argus II, proved that electronic vision was possible but often provided only crude shapes or light perception. The PRIMA trial is notable because it moved the needle toward functional form vision. The average gain among participants was approximately 25 ETDRS letters—more than five lines on a standard eye chart.
The human element of this transition is illustrated by participants like Sheila Irvine, who joined the trial at Moorfields Eye Hospital in London. After implantation and a period of rehabilitation, Irvine was among those who could again read letters and numbers. This highlights a critical part of the treatment: the “learning curve.” Patients do not wake up from surgery with crisp vision; they must undergo training to teach their brains how to interpret the new electronic signals as familiar objects and patterns.
Comparing Modern Vision Interventions
We see common to group all advanced eye treatments together, but the current landscape for geographic atrophy is divided by objective. While some treatments protect what remains, the PRIMA system is designed to replace what is gone.
| Approach | Primary Goal | Capability | Key Limitation |
|---|---|---|---|
| Complement-inhibitor drugs | Slow progression | Reduces lesion growth | Cannot restore lost vision |
| Low-vision aids | Daily coping | Magnifies existing sight | Relies on remaining vision |
| Retinal prosthesis (PRIMA) | Restore central function | Enables recognition of forms | Requires surgery and training |
Risks, Constraints, and Clinical Reality
Despite the promising data, the procedure carries significant risks. Subretinal surgery is invasive. The clinical data reported 26 serious adverse events across 19 participants, including retinal tears, increased eye pressure, and subretinal blood. While 95% of these events resolved within two months of implantation, they underscore the seriousness of the intervention.
We find also strict candidacy requirements. The device is specifically for those with geographic atrophy where the photoreceptors are gone, but the “downstream” retinal circuitry remains healthy enough to be stimulated. Those with different causes of blindness may not be candidates.
the resolution of the implant—using 100-micrometer pixels—means it cannot replicate the million-pixel clarity of a healthy human eye. Without digital zoom, the practical ceiling for resolution is estimated around 20/420. The goal is not a return to 20/20 vision, but a shift from a total central void to usable visual information.
The Path to Regulatory Approval
As of March 2026, the technology is in the final stages of the regulatory pipeline. Science Corporation, the developer of the system, has submitted applications for both a CE mark in Europe and approval from the U.S. Food and Drug Administration (FDA). A European launch is anticipated later in 2026, though the device is not yet available as a routine clinical option.
Future research is expected to focus on the durability of the implants over several years and whether further reductions in pixel size can increase visual acuity. There is also a significant interest in optimizing the software to reduce the rehabilitation time for new users.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult with a board-certified ophthalmologist to determine candidacy for any retinal prosthesis or AMD treatment.
The next major checkpoint for the technology will be the official regulatory decisions from the FDA and European authorities, which will determine the timeline for wide-scale clinical availability. We will continue to track these filings as they progress.
Do you or a loved one live with macular degeneration? We invite you to share your experiences and questions in the comments below.
